Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 4.97K
-0.74%+3.45%+25.32%+60.57% 262B
-0.83%+0.90%+8.15%+25.65% 167B
-3.25%-4.44%-18.45%+67.21% 156B
-1.17%-8.32%-58.35%-16.30% 61.87B
-2.53%+3.53%+10.46%+47.87% 54.44B
0.00%+2.46%-11.97%-6.29% 53.3B
-3.47%+1.28%+22.27%+73.26% 51.07B
+0.70%-2.89%+10.06%+64.86% 50.25B
-3.63%+1.99%+34.93%+95.47% 47.17B
Average -1.45%+1.68%+2.49%+45.81% 100.29B
Weighted average by Cap. -1.48%+2.44%+5.25%+48.06%
Logo SpectraScience, Inc.
SpectraScience, Inc. is focused on developing its WavSTAT Optical Biopsy System (WavSTAT). The WavSTAT employs a risk technology that optically illuminates tissue in real-time to distinguish between normal and pre-cancerous or cancerous tissue. The Company has developed a technology platform to determine if tissue is normal, pre-cancerous or cancerous, without the need for a physical biopsy. The WavSTAT4 Optical Biopsy System operates by using cool, safe ultraviolet (UV) laser light to optically illuminate and analyze tissue, enabling the physician to make a diagnosis during endoscopy when screening for cancer and, if warranted, to begin immediate treatment during the same procedure. The WavSTAT4 uses laser-induced auto-fluorescence to obtain spectral information from tissue at the suspected site. The system is classified as a non-significant risk device, which transmits low-level UV laser light energy through an optical fiber to the tissue through the working channel of an endoscope.
Employees
7
  1. Stock Market
  2. Stocks
  3. SCIE Stock